Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
How It Works 
News - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI Summary - About
Avalo Therapeutics Inc(AVTX)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for AVTX
09/25/2026: AVTX (1-star) is currently NOT-A-BUY. Pass it for now.
Avalo Therapeutics is a clinical-stage biotechnology company focused on developing targeted monoclonal antibody therapies for inflammatory diseases. The company is currently undergoing a strategic transformation, concentrating its resources on its lead asset, AVTX-009, to address unmet needs in immunology. Its primary growth opportunity lies in the successful advancement and potential commercialization of this lead program. However, the company faces substantial risks, including the absence of current revenue, high R&D cash burn, and intense competition from established pharmaceutical players. The stock is a high-risk, high-reward proposition suited primarily for growth-oriented investors who can tolerate significant volatility and the inherent uncertainties of drug development.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Mixed fit | The company offers high-risk, high-reward potential based on clinical trial success, but lacks established growth metrics. |
| Momentum investor | Weak fit | Momentum is generally dependent on clinical news flow rather than sustained price trends, making it suitable only on specific, positive clinical signals. |
| Value investor | Weak fit | There are no earnings or cash flows to support a traditional value-based investment thesis. |
| Dividend investor | Weak fit | The company does not pay a dividend and focuses all capital on research and development. |
| Low-risk investor | Weak fit | Clinical-stage biotechnology stocks involve extreme volatility and high risk of capital loss. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | Clinical-stage stocks are prone to extreme price swings based on trial results and regulatory announcements. |
| Valuation risk | High | Valuations are highly speculative as they rely on the potential future success of unproven drug candidates. |
| Competition risk (immunology biologics) | High | Avalo competes against well-funded pharmaceutical firms with established commercial products. |
| Business quality | Medium | As a development-stage entity, the business quality is defined by its pipeline potential rather than current operational stability. |
| Dividend income | Low / none | The company provides no income to shareholders. |
| Execution risk | High | Success depends entirely on the company's ability to execute complex clinical trials and achieve regulatory approval. |
Price Behavior
Rolling Over
The price momentum is slowing down and beginning to turn downward.
Extreme Price Shocks
The stock has experienced exceptionally large and disruptive price movements during the period.
Analysis of Past Performance
Type Stock | Historic Profit -2.96% | Avg. Invested days 25 | Today’s Advisory PASS |
Upturn Advisory Rating  | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/25/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 843.06M USD | Price to earnings Ratio - | 1Y Target Price 44.08 |
Price to earnings Ratio - | 1Y Target Price 44.08 | ||
Volume (30-day avg) 1.0M shares | Beta 0.79 | 52 Weeks Range 12.41 - 24.27 | Updated Date 09/25/2026 |
52 Weeks Range 12.41 - 24.27 | Updated Date 09/25/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -4.41 |
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Clinical Development | Research and development of immunology drug candidates like AVTX-009. | The company is currently burning cash to fund research, with no products on the market to generate revenue. |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Valuation
Trailing PE - | Forward PE - | Enterprise Value 420.50M | Price to Sales(TTM) 14289.21 |
Enterprise Value 420.50M | Price to Sales(TTM) 14289.21 | ||
Enterprise Value to Revenue 7127.2 | Enterprise Value to EBITDA -0.19 | Shares Outstanding 53.63M | Shares Floating 40.11M |
Shares Outstanding 53.63M | Shares Floating 40.11M | ||
Percent Insiders 1.69 | Percent Institutions 133.63 |
Upturn AI Summary
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
About Avalo Therapeutics Inc
Exchange NASDAQ | Headquarters Wayne, PA, United States | ||
IPO Launch date 2015-11-13 | President, CEO & Director Dr. Garry A. Neil M.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 33 | Website https://www.avalotx.com |
Full time employees 33 | Website https://www.avalotx.com | ||
Avalo Therapeutics, Inc., a clinical stage biotechnology company, develops IL-1ß-based treatments for immune-mediated inflammatory diseases in the Unites States. Its lead product includes AVTX-009, a humanized monoclonal antibody that binds to interleukin-1ß, which is in phase 2 clinical trial to treat inflammatory diseases. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Wayne, Pennsylvania.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.